[{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ University of Georgia Research Foundation"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aruna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB126","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aruna Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Aruna Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AB126 is an unmodified neural-derived exosome that can traverse the blood-brain barrier, showing anti-inflammatory and neuroprotective properties for acute ischemic stroke treatment.

                          Product Name : AB126

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 16, 2024

                          Lead Product(s) : AB126

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AB126, an unmodified exosome derived from neural stem cells, has broad therapeutic, which is investigated in superoxide dismutase 1 amyotrophic lateral sclerosis (ALS) mouse model.

                          Product Name : AB126

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          July 09, 2023

                          Lead Product(s) : AB126

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AB126 are allogenic neural exosomes derived from neural stem cells, is highly effective at crossing the blood/brain barrier – so it can carry other molecules across.

                          Product Name : AB126

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 13, 2022

                          Lead Product(s) : AB126

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Preclinical

                          Sponsor : University of Georgia Research Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : AB126 is an unmodified neural-derived exosome with the innate ability to cross the blood-brain barrier. AB126 is designed to provide potential therapeutic benefit in its native form for multiple different neurological indications.

                          Product Name : AB126

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 10, 2022

                          Lead Product(s) : AB126

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : The award will support advancement of AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI).

                          Product Name : AB126

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 31, 2022

                          Lead Product(s) : AB126

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Preclinical

                          Sponsor : National Institute of Neurological Disorders and Stroke

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank